compani attend annual snowbird confer takeaway
cover compani follow
singl theme unit med-tech space
found sever manag team optimist outlook
note invest made product clear
begin pay hand compani
point plan increas spend year ahead make
invest year instead
publicli trade compani relev space includ
buy pt varex imag corpor rate
medic privat renovia privat
takeaway particip orthoped compani
publish ryan zimmerman separ research note
pleas read import disclosur analyst certif appear appendix
list market capit descend order also spoke
manag buy pt recent although
compani attend snowbird healthcar confer includ
highlight discuss
met vice presid investor relat ryan weipsfen
director investor relat mark wilterd
follow last quarter earn call press detail
robot program compani would divulg detail design
wrist devic like da vinci caution reli prior revenu
target provid prior analyst day
paclitaxel drug-coat balloon compani hope sponsor
present upcom confer viva vascular confer
novemb could see favor data prove safeti influenti
public like journal american colleg cardiolog jacc
anecdot ad continu see support among doctor
despit neg public follow decemb jama articl
increas risk death paclitaxel dcb use treat femoropoplit
medtron offer neurovascular diseas also topic interest
prospect futur innov compani offer limit detail except
say chang state guidelin stroke triag continu drive
thrombectomi usag specif state modifi protocol
push first respond train identifi sever stroke patient
transport facil best abl treat previou
guidelin steer stroke patient closest hospit mani patient
languish await transport hospit equip perform
neuro-endovascular surgeri rhode island one exampl state
saw doubl thrombectomi procedur stroke guidelin chang
implement
touch spine segment manag ask mazor
placement strategi level implant pull-through manag
indic still earli day mazor stealth door
open compani industri broadli compani opin
overal spine busi ripe consolid greater use
enabl technolog imag drive time compani
forese busi whittl player appetit
compani ask regard interest acquir buy
pt analyst ryan zimmerman compani would definit
confirm deni get sens much interest
line compani believ opportun improv mazor
portfolio via enhanc intend cut procedur time
lastli perspect offer diabet franchis
compani agre view industri much consumer-
driven model win market entail product placement
market close patient though compani pleas
portfolio particularli area like artifici pancrea clear leader
key game-chang elimin use finger-stick
met outgo vice presid investor relat david erickson
cover array topic includ litig abbott
neutral investor expect low-risk perspect
compani recent ce mark mitral repair product pascal edward
confirm suffici inventori commerci would
provid date devic might launch eu suspect
relat on-going litig brought abbott alleg patent infring
though manag would comment rang potenti
outcom realist anticip litig could drag multipl
year similar past lawsuit addit manag reiter comfort
mitral/tricuspid revenu guidanc
turn expect low-risk trial upcom
confer manag remind investor room trial
clearli design toward non-inferior superior manag opin
expect superior may wall street issu
size address low-risk pool manag would provid rang
except suggest previou estim size low-risk pool
largest cohort dwindl consider year
prospect dtc market tavr patient also address
manag opin real upsid broad-bas campaign
given minuscul size patient pool patient rel
gener popul similar observ last year
appear though concret strategi unlik
compani opt mass dtc campaign
respect buy pt upcom lotu launch
compani realist anticip cede share howev compani
certain lotu broad label corevalv
edward sapien could work advantag heard
may roll valv size also possibl
doctor europ may will implant lotu valv given
taint histori market recal investor also ask ew
current share market given valv commerci within
month eu corevalv sapien share fairli close
note mdt present crt confer week
compani believ hold share eastern europ
 sapien enjoy two-year headstart clearli cede share
japan doesnt appear good data sapien like
lead given head start crt confirm corevalv hold
met vice presid investor relat michael watt manag
investor relat richard lepk discuss focus factor
underli improv perform core busi breast health
diagnost guid growth outlook potenti futur
manag continu feel import stori
futur agre compani like target near-term
acquisit aesthet space would instead use in-licensing-typ
relationship area also think compani unlik engag
larg acquisit next coupl year instead discuss
recent earn call expect manag priorit smaller deal well
stock repurchas
holog leadership strive attain consist predict growth new
product breast health divis includ smartcurv clariti hd
support sustain growth sold larg
portion instal base refresh breast health salesforc
work sell entir portfolio instead mainli capit equip allow
sell across patient continuum screen biopsi surgeri
express optim around core busi manag note
work continu view guidanc
achiev help higher growth busi
stabil perform core busi
met execut vice presid strategi corpor develop
steven pacelli vice presid corpor develop matthew dolan
price headwind continu domin investor discuss
manag emphas higher cgm adopt partial usher
market entranc abbott neutral libr product
offset competit threat price pressur addit
express confid dexcom product featur fare well
face anticip libr launch
continu priorit progress toward expand manufactur
capac develop pipelin product includ line extens
like direct-to-watch like compani extens product
innov admit good idea competit
price affect busi long term
met cfo jeff elliott though group meet larg
introductori client less familiar stori much meet
recap newer growth driver includ invest
develop cologuard longer test sampl life lower fals
posit rate expans ob-gyn gi channel seek
approv cologuard approv age group develop new
compani also ask prospect competit manag
opin credibl competitor would year behind one
follow timelin toward approv specif took
roughli month enrol patient trial follow
anoth year follow-up prior fda submiss fda decis came
anoth year key variabl also time around accept
uspstf guidelin next task forc meet schedul
afterward may take anoth year ramp commerci coverag
besid long-term growth driver outlin continu
tangibl opportun around greater penetr hospit system
better integr physician offic practic compani partnership
epic allow
met chief offic micah young vice presid
busi develop investor relat eli kammerman
recent spent time manag team non-deal
roadshow week februari link note use snowbird
meet discuss pipelin product
learn yet receiv fda clearanc alert clinician
hypoxemia hyperoxemia low high oxygen
hypoxemia featur would give earli warn second one minut
patient anticip crash low oxygen give clinician
opportun intub faster hand hyperoxemia
custom would includ anesthesiologist pre-op set
respiratori therapist hospitalist internist icu set
manag express enthusiasm futur in-hom monitor
patient prescrib opioid parker utah spur chang local
level accord manag larg utah hospit system alreadi send
devic home patient prescrib opioid envis
consumer-friendli less expens devic would avail patient
hospit discharg either prescript counter like masi
oper perform technolog platform product pipelin
met cfo matt garrett execut vice presid global
strategi corpor develop derrick sung
compani ask expect appl heart studi
buy pt analyst walter piecyk late-break clinic trial
upcom meet saturday march appl watch sensit
specif expect unveil public first time
whatev outcom compani believ widespread use ecg
screen net posit increas monitor patient
even thought asymptomat may feeder drive patient
cardiologist set even current fals posit rate quit
high continu alert drive unnecessari visit pcp
cardiologist anecdot manag heard report
provid even turn away patient book appoint
turn zio manag continu pleas ramp
describ uptak strong without quantifi specif part
manag believ number misconcept
marketplac includ optim wear time whether
applic monitor type regard manag observ
everi cardiologist opt irhythm manag note
time forese extended-wear monitor eventu take share away
compani remain pleas previou annual salesforc target
per rep continu move upward manag still see
growth mani matur sizabl account like kaiser stanford
manag credit salesforc deliv servic beyond tradit
sale truli assist client full process on-board follow-
met steve reichl cfo compani
recent frame potenti revenu rang multi-year goal
question focus build block drive
recal compani provid framework investor think
revenu goal placement although
would prefer specif rang manag suggest
mani investor prefer work underli assumpt placement
capit mix annuiti stream view given consist street
miss gap compani estim investor
expect need narrow point manag reassur
us intern forecast improv substanti
result met compani estim
term geograph mix compani remain encourag strong
demand eu howev pheno mainli posit
icu/crit care system placement volum strong
less test util manag hope new eu leadership
develop stronger relationship clinic champion hospit
set rather leav system triag compani
see opposit dynam system place test run
immedi topic pushback test price manag
confirm see hand case account adopt molecular
diagnostic-typ model even flexibl reagent model solidifi
cover hand topic manag convey optim
regard newli strengthen salesforc best-in-class
sale rep train better deliv enhanc messag addit
grow bodi support data pheno outcom better refin
sale pitch one potenti catalyst previous discuss mayo clinic-
ucla studi could present american societi
microbiolog asm confer may
regard futur expans pheno china acceler explor
potenti joint ventur distributor arrang compani confid
prospect lean manag prior relationship
distributor previou posit roch rhhbi rate
didnt attend year confer spoke recent
chief scientif offic jame dempsey phd mridian system real-
time adapt therapi latest advanc mridian
smartvis mri real-tim adapt therapi learn system
capabl less millisecond latenc visual
allow see cancer tissu respond radiat
enhanc also bring faster multi-leaf collim doubl
speed mr imag frames/second allow lower latenc
doubl imag resolut two-fold improv mr signal-to-
nois ratio addit smarttarget featur turn radiat beam
automat adjust tumor organ movement like
vray technolog continu innov
met establish lab manag team includ ceo juan jose
chacon quiro cfo rene gaeta chairman nick lewin meet
cover array topic special focu timelin around proprietari
surgeri techniqu motivamint
respect upcom fda advisori committe panel gener
plastic surgeri devic march compani anticip heavi news
flow given breast implant tend scrutin topic media
follow neg icij report compani would surpris
consider neg attent textur breast implant given
dynam europ compani appear less concern given
share textur implant alreadi modest note
motiva ergonomix implant consid smooth
manag receiv mani question timelin minim invas
techniqu motivamint compani confirm complet
work anim cadav complet last pilot work
human manag feel technic challeng aspect
develop special deliveri system implant though compani
seen signific delay yet specif implant procedur
requir electrocauteri reli blunt dissect therebi
minim surround tissu damag procedur time short
minut goal get time minut matter
perspect surgeon perform regular implant quick
minut averag surgeon need minut hour surgic
implant effort prove success could appeal women
shi away surgeri given predisposit keloid scar and/or
hyperpigment ethnic group high melanin term
timelin manag hope launch japan end entri
china might farther away manag hope
leverag foreign trial data perhap data work done korea
chines regul begin accept result studi perform
oversea although manag anticip uptick procedur
much faster asian countri could market smaller less
invas implant particularli among women look size
cc implant term big could compani
note roughli women use pad bra extra lift
final time eu compani explor possibl
submit usabl studi data cover month eu
regul find accept compani may obtain ce mark mid-
term new market manag enthusiast entri
thailand taiwan thailand project one largest
market asia women australia fli thailand
annual breast implant turn taiwan also substanti
opportun captur market share given two
manufactur market implant allergan rate
met chief offic shig hamamatsu vice presid
financ investor relat steven anheier spent meet
focus recent china joint ventur type licens
opportun manag express enthusiasm jv note
gener manag tomoknif current distributor china
slate becom ceo jv think may reduc amount
disrupt transit tomoknif jv addit
transit tomoknif continu pursu new order convert
exist order revenu sinc still underli financi incent
view import see whether revenu continu flow
earlier chines order hope manag
will give indic futur earn call
continu think last quarter strong order result china
order driven larg excit momentum around recent
releas quota licens hope order demand china remain
strong throughout remaind know capit equip
order hard predict often lumpi quarter quarter
anticip licens serv strong catalyst
understand difficult predict market share might abl
eventu claim quota expect significantli
higher estim high-single-digit market share compani hold
outsid china manag note last report quarter show
continu strength japan consist perform emea good
growth america rel weak year-over-year comp
met chief offic john landri newli
public yet report quarter much discuss focus basic
busi new precis hi-vni system launch mid-
februari allow compani market system mask-fre form
non-invas ventil non-inferior non-invas posit pressur
ventil new system expect come significantli higher
price point dispos use latest gener
system prior version think loyal follow
might open small price increas dispos think
compani plan take strategi
howev pipelin product like may abl command
higher price point regard continu think product
offer autom control may signific potenti beyond
neonat icu though clinic work would need perform
met chief execut offic frank amato chief scienc
strategi offic jp errico given focu revenue-gener gammacor
prescript much discuss manag dealt
recent insur win late februari highmark region cross
shield payor pennsylvania delawar west virgina announc
coverag gammacor polici state devic may medic
necessari treat episod migrain episod cluster headach
manag note polici compani coverag patient
expect result in-network patient fulli cover out-of-
network patient pay pocket
like win fact highmark region insur mean
larg proport patient region gammacor
coverag enabl target prospect prescrib
region coupl quarter coverag give us better
understand demand revenu look like well-reimburs
set may allow us extrapol expect entir countri
forecast purpos believ doctor will keep
prescrib gammacor truli desper patient wait least
patient coverag practic becom consist
anoth recent reimburs win earli januari announc
five-year feder suppli schedul contract award va
hospit key target account cover
territori manag compani sale rep expect
help increas revenu convers come quarter
highmark nearli million cover us
live manag express continu confid target million
cover us live million cover us live end
look forward continu posit updat pbm payor
expect gap revenu prescript gradual narrow
next sever quarter
met chief execut offic john onopchenko manag
dedic resolv debt matur first half
seem agre view debt overhang
stock weve written believ debt address
elgx share could move higher anticip announc
transact settl matur present view near-term
catalyst share chanc manag continu solidifi
credibl elgx turnaround stori continu recommend elgx
met ceo kelli huang cfo plovan main question
mind commerci obalon navig touch
dispens trend week launch
much new inform manag could provid investor
said manag emphas difficulti instal x-ray capabl
adjunct practic capit outlay certif
licens physicist manag ad way navig
actual demonstr intens underli interest
discuss new physician patient assist ambassador program
patient interest continu strong time interest-to-consult
consultation-to-treat lag especi among bariatr surgeon
along call center support nutrit consult servic
ambassador program intend drive pull-through sustain
compani focus commerci execut near-term
ask innov possibl trend futur
compani suggest could develop longer durat
balloon inflat passabl way away
met chief offic erick lucera valerita set report
earn later month discuss limit recent
reimburs win effort add addit servic v-go patient
januari valerita announc v-go receiv prefer statu
humana part optumrx formulari applaud win
manag note like earli expect impact sale
product must put account formulari list
individu compani reimburs team start work
go account account request v-go ad formulari list
think earliest prefer statu could start becom tailwind
back half
mid-januari valerita partner digit diabet coach compani
cecelia offer expert support v-go patient find
meaning relationship could offer better diabet manag
patient allow valerita sale rep spend time sell
account instead educ consult patient top
manag note compani put system place
reduc sale rep time devot paperwork administr task
may seem like small step think extra time could eventu
start pay form closer relationship account higher
sale look forward updat compani feedback
recent free good program expand salesforc
lastli note recent day vlrx share hover around
exercis price level seri warrant difficult
predict time warrant holder may choos exercis
think import correspond cash becom avail valerita
next coupl quarter
btig cover compani mention report
appendix analyst certif import disclosur
